Elutia Inc. (ELUT) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Margin (GAAP) | 57.90 percent | FY2026-Q1 |
| Adjusted Gross Margin Excluding Intangible Asset Amortization | 66.50 percent | FY2026-Q1 |
| Net Sales from SimpliDerm Product Line | 2.1M | FY2026-Q1 |
| Net Sales from Cardiovascular Product Line | 1M | FY2026-Q1 |
| Adjusted Earnings Before Interest Taxes Depreciation and Amortization | 4.41M | FY2026-Q1 |
| Value Analysis Committee Approvals for EluPro | 160.00 | FY2025-Q4 |
| Net Sales from Bioenvelope Device Protection Products | 3.5M | FY2025-Q2 |
| EluPro Share of Ongoing Bioenvelope Sales | 52.00 percent | FY2025-Q1 |
Back to ELUT overview · ELUT earnings · ELUT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.